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                                          ABSTRACT 
VEGF INDUCED DIFFERENTIATION OF GINGIVAL STEM CELLS TO 
ENDOTHELIAL CELLS IN VITRO  
 
DEGREE DATE: JUNE 21, 2019 Garima Gupta, D.D.S. 
COLLEGE OF DENTAL MEDICINE NOVA SOUTHEASTERN UNIVERSITY 
Directed by: Dr. Umadevi Kandalam, Associate Professor, Department of Pediatric 
Dentistry, NSU College of Dental Medicine.  
Background: Birth defects that result in structural malformation of major organs 
are one of the major causes of mortality in children.  Tissue engineering and 
regenerative medicine (TERM) strategies are particularly beneficial for the 
pediatric patients to correct these defects owing to their greater regenerative 
capacity compared to the adult population. Limited availability of pediatric patient’s 
auto-transplantation of organs makes TERM strategies as a promising alternative 
to conventional clinical procedures that utilize the grafts. Recent developments in 
stem cells technologies, there is an enormous potential for TERM in correcting 
birth defects and enhancing the life span in young population. However, the major 
challenge to the craniofacial bone tissue engineering is the repair and regeneration 
of critical size bone defects accompanied by functional vascular network. 
Insufficient vasculature in regenerated bone is the main causes of large graft 
failure, leading to inner graft necrosis and lack of integration with the host tissue. 
While, it is well established that human gingiva derived mesenchymal stem cells 
(GMSCS) are robust source of osteogenic precursors in bone regenerative TERM, 
it is unknown if GMSCS also can differentiate into endothelial cells. The aim of this 




Methods: GMSCs were cultured under standard conditions. The angiogenic 
differentiation was induced administering Vascular Endothelial Growth Factor 
(VEGF).  The expression of endothelial marker gene expression was measured by 
using quantitative PCR method. A functional tube formation assay was performed 
to assess the endothelial differentiation. Immunofluorescence was conducted to 
detect the surface marker protein CD31.  
Results: Our results showed a dose dependent increase in the expression of the 
endothelial marker genes, PECAM-1, VCAM-1, KDR, FLT-1 and PCDH12. The 
tube formation assay revealed the ability to form capillary structures in the cells 
induced with 10 and 50ng/ml VEGF. The data on Immunofluorescence 
demonstrated the distinct presence of CD31 surface marker. 
Conclusions:  Our results showed that GMSCS have the potential to differentiate 
into endothelial cells. Thus, they serve as sources for programmed angiogenic and 
osteogenic cells to contribute for the regeneration of the vascularized bone to 
make a paradigm-shift in stem cell therapy. 
 
Key words: Gingiva derived stem cells, Vascular endothelial growth factor, 
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CHAPTER 1 INTRODUCTION 
1.1 Craniofacial Bone Formation Key Considerations 
Bone is a dynamic and highly vascularized tissue that contains extracellular matrix 
composed of inorganic and organic elements that contains a number of types of 
cell that are responsible for its metabolism.1 The formation of bone is multi-step 
process with the interactions among various cells, extracellular matrix and organic 
and inorganic molecules. In particular, during craniofacial bone development, 
many biophysical forces, particularly mechanical load and locally released growth 
factors are important regulatory factors.  Additionally, craniofacial skeleton 
involved in specific function such as protection of brain and optic tract, while 
facilitating mastication.2  
1.2 Clinical Relevance 
Birth defects that result in structural malformation of major organs are one of the 
major causes of mortality in children. Craniofacial bone defects due to congenital 
anomalies, cancers, and trauma and fractures are most common. While the birth 
defects with congenital malfunctions are 2-3%, the prevalence of craniofacial 
fractures in pediatric population is 58% of total fractures annually. While treatment 
of cranial vaults needs permanent protection, reconstruction of segmental defects 
requires restoration of mechanical integrity and temporal joint function. Unlike adult 
patients, reconstruction of these mandibular and maxillo-facial bones in growing 




achieve optimal restoration of mastication, deglutition, and cosmetic issue. Thus, 
the medical cost associated to repair of these defects, in particular the critical size 
defects are over $2.5 billion/annum.3,4 
1.3 Critical Size Defects and Current Treatment Modalities 
A critical size bone defect is a large void in a bone beyond a critical healing 
threshold, which cannot heal spontaneously. Attempting the repair in the absence 
of bone grafts can impede the healing processes accompanied by osteogenesis, 
which results in formation of fibrous connective tissue rather than bone  warrants 
the need of bone grafts.5  Currently, 2.2 million bone graft procedures are 
performed around the world each year  to repair the critical size defects.3  The 
current gold standard treatment for reconstruction of critical size bone defect in the 
craniofacial region is the implantation of autologous bone graft. Bone graft from 
extra oral surgical harvest site commonly includes tibia and ilium. However, for 
pediatric patients, graft harvest from autologous sites increases the additional risk 
and morbidity of a second surgical procedure, the donor site morbidity and low 
availability. Allografts, on the other hand, are concerned of risk for viral infections. 
In addition, there is increased unpredictable outcome using  the bone grafts, when 
bone defect size is greater than 4 cm.6 All these drawbacks associated with grafts 
call for the development of stem cell-based tissue engineering strategies as a 
promising  alternative way to regenerate bone.4,7-11 
1.4 Bone Tissue Engineering  
Human stem cell-based tissue engineering emerged as a viable option for the 




mains components of the “golden triad” of tissue engineering which includes cells, 
growth factors and scaffolds6 (Figure 1). However, the challenges in bone tissue 
engineering include induction of proper vasculature at the defect site in the 
regenerated bone tissue. 
 
 Figure 1: Essential Components of Tissue Engineering  
 
1.5 Significance of Vascularization in Bone Regeneration  
The clinical success of bone tissue engineering lies on developing a functional/vital 
bone with efficient vascularization. Bone formation indeed can progress 
successfully if there is adequate vascularization at the site. In addition to the bone 
formation, vasculature is also essential for bone remodeling during fracture healing 
and therefore, angiogenesis is a key component in bone repair.12,13 Defective 




osteomyelitis and delayed fracture healing or non- union.12,14 Osteonecrosis or 
avascular necrosis happens when there is inadequacy of blood supply to the bone, 
leading to death of bone cells. Osteomyelitis is an infection within the bone, which 
is mainly caused by poor vascularization.12 Thus, bone vasculature is not only 
essential for regeneration, remodeling and homeostasis but is also essential for 
maintaining the functional integrity and longevity in the host.13-16 While the gold 
standard autologous bone grafts have a pre-existing vascular network that meets 
the demand of oxygen and nutrients supply, the engineered grafts are, in general, 
incapable of generating sufficient vasculature. Vascularization supports bulk 
transport of nutrients and convective oxygen transport. However, although 
spontaneous vascularization does happen in the host to the graft, the vessel in-
growth is too slow to provide adequate nutrient and oxygen transport to the cells 
in the deeper regions.  Therefore, the engineered grafts have to rely mainly on 
passive diffusion of nutrient and oxygen, which is often insufficient, resulting in 
graft failure. Several strategies have been experimented to enhance 
vascularization including pre-vascularization of scaffolds and utilizing two co-
culture methods, where endothelial cells will be co-cultured with stem cells.  
1.6 Currently Available Techniques to Induce the Vascularization in 
Regenerating Bone Tissue 
There are numerous methods to increase vascularization in bone tissue 
engineering; 1) combination of scaffold and angiogenic growth factors, and 2) ex-
vivo pre-vascularization (i.e. co-culture of endothelial and osteogenic cells) 




1.6.1 Combination of Scaffold and Angiogenic Growth Factors 
A method of increasing vascularization in bone regeneration engineering by 
scaffold combined with angiogenic growth factors (VEGF, FGF). Hydrogels and 
other soft materials have been developed as suitable matrix materials for 
osteogenesis and angiogenesis due to their characteristic of loading with cells at 
relatively high density and retaining cell viability for longer period.17 Nonetheless, 
there are some drawbacks associated with this technique, including, disruption of 
hydrogel structure and poor integration with the host tissue.6 Although, 
incorporation of the angiogenic growth factors onto the scaffold has been shown 
to accelerate vascularization, it has been considered as a relatively inefficient 
process for bone formation, and presents the difficulty in selecting proper dosage 
of growth factor onto the scaffold with co-culturing between mature endothelial 
cells and osteogenic cells. These shortcomings include limited in vitro expansion 
of the endothelial cells.2 It is also concerned if multiple different cell types can grow 
in concert to develop a structured bone tissue in the same ex-vivo culture. An 
another approach in the co-culture is to use different ratios of each cell type, but 
the main problem in this technique is to explore a way to identify different cell 
types.7  
1.6.2 An ex-vivo Pre-vascularization (i.e., Co-Culture of Endothelial and 
Osteogenic Cells)  
This technique utilizes co-culture of mature endothelial cells and osteogenic cells. 
Although mature differentiated endothelial cells may be used for bone tissue 




culturing between mature endothelial cells and osteogenic cells. These 
shortcomings include limited capacity to expand endothelial cell  in vitro.2 It is also 
concerned if multiple different cell types can grow in concert to develop a 
structured bone tissue in the  ex-vivo co-culture. Another approach in the co-
culture is to use different ratios of each cell type, but the main problem in this 
technique is to explore a way to identify different cell types.7  
1.7 Proposed Method to Induce Vascularization (GMSCs to Endothelial cells)  
Based on the possible drawbacks of aforementioned techniques, we proposed in 
this study to differentiate mesenchymal stem cells derived from human gingiva 
(GMSCs) into endothelial progenitor cells (EPC) via stimulation with vascular 
endothelial growth factor (VEGF). In that way, it will reduce the drawbacks 
associated  with transplantation of ex vivo co-cultured osteoblasts and endothelial 
cells in a scaffold, which require appropriate ratio of both cell types and other 
techniques using specially designed scaffolds.2 The endothelial progenitor cells 
(EPC) are the ones with enhanced proliferative capacity and generates all subsets 
of endothelial cell lineage upon differentiation. It has been found that EPC have a 
higher survival rate as compared to mature endothelial cells (most commonly used 
human umbilical vein endothelial cells, HUVECs).7 Furthermore, EPC have been 
shown to be 10 times more proliferative than HUVECs.12  
The stem cell source that contains both osteogenic and endothelial progenitor cells 
is considered to be the most advantageous cell source.2 Our lab has already 
established the osteogenic potential of GMSCs. By this method, it would be 




vasculogenic progenitor cells, rather than adding exogenous endothelial and 
osteoblast cell types to enhance angiogenesis during bone regeneration.  
1.8 Gingival Mesenchymal Stem Cells (Cells Used in This Study) 
In this study, we chose to use GMSCs. These cells are of special interest as they 
serve a promising cellular source especially in craniofacial tissue regeneration. 
90% of the GMSCs are derived from cranial neural crest cells and they differentiate 
into cartilage and bone to form vast majority of craniofacial structures.4,13,14 
Moreover, mesenchymal stem cells deriving from gingival tissues are  minimally 
invasive and are easily accessible18-22 (Figure 2). GMSCs have the ability to 
proliferate faster than bone marrow  stem cells, exhibits a stable morphology even 
after extended passaging and have potent immunomodulatory characteristics.18,19 
Furthermore, neural crest originated stem cells like GMSCs might be more efficient 
in regenerating bone in craniofacial region, when compared to the bone marrow 







Figure 2: Sources of oral stem/progenitor cells isolated. DFSCs: dental follicle stem cells, 
G-MSCs: gingival mesenchymal stem/progenitor cells, PDLSCs: periodontal ligament stem 
cells, SHEDs: stem cells from the human exfoliated deciduous teeth, DPSCs: dental pulp 
stem cells, BM-MSCs: bone marrow mesenchymal stem cells, and SCAP: stem cells from 
the apical papilla (Reference: Fawzy El-Sayed KM, Dörfer CE. Gingival Mesenchymal 
Stem/Progenitor Cells: A Unique Tissue Engineering Gem) 
 
1.9 Growth Factors 
Growth factors are biological macromolecules which play an important role in 
regulating cell growth, differentiation and migration by targeting specific cellular 
receptors. Angiogenic growth factors are commonly expressed in response to 
injury and are produced by inflammatory cells and stromal cells to stimulate growth 
of blood vessels. There are several angiogenic growth factors that include vascular 




growth factor (TNF-α), transforming growth factor beta (TGF-β), and the 
angiopoietins. Among these, the most commonly considered proangiogenic factor 
is vascular endothelial growth factor (VEGF).6,13,26,27 
1.10 VEGF 
The VEGF family consists of seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-
D, VEGF-E, VEGF-F, PIGF. All of the 7 members share common homology 
domain. VEGF original name was vascular permeability factor as it increases 
microvascular permeability and fenestration. VEGF has multiple functions in 
conditioning of angiogenesis as well as during angiogenesis processes. It 
stimulates proliferation, migration of endothelial cells which results in the formation 
of new blood vessels. Furthermore, studies have a shown that VEGF also 
facilitates tube formation and engages in differentiation of endothelial progenitor 
cells.6,13,26,27  
1.11 Endothelial Cells  
Studies have shown that endothelial cells can enhance bone regeneration ability. 
Endothelial cells are the key cellular element that compose blood vessels and 
capillaries (Figure 3). Endothelial cells are directly related to angiogenesis and  





Figure 3: Endothelial cells 
 
1.12 Mechanism how VEGF Stimulates Endothelial Cell Formation 
VEGF is an angiogenic growth factor that works by binding with its two- cognate 
receptor type tyrosine kinases, VEGFR1, VEGFR2 which, in turn, elicits cell 
signals to induce angiogenesis.13 
VEGF activates the phosphorylation of histone deacetylase 7 (HDAC7) via a 
PKC/PKD1 pathway. HDAC7 is mainly restricted in the nucleus of endothelial cells. 
HDAC7 phosphorylation stimulates nuclear export of HDAC7, which leads to 
activation of VEGF responsive genes. RCAN2 and Nur77 are the VEGF regulated 
genes required for migration and proliferation of endothelial cells.28 In summary, 
VEGF signaling activates phosphorylation of HDAC7 and it regulates the 





Figure 4:  Mechanism of VEGF stimulating angiogenesis (Reference: Wang S, Li X, Parra M, 
Verdin E, Bassel-Duby R, Olson EN. Efficient Differentiation of Bone Marrow Mesenchymal 
Stem Cells into Endothelial Cells in Vitro) 
 
1.13 Endothelial Marker Genes Used in This Study   
The angiogenic differentiation of gingival stem cells were identified by the 
expression of these endothelial marker genes: VCAM-1, PCDH12, VEGF 
receptors (FLT1 and KDR), PECAM-1. Following are the endothelial markers that 
have been evaluated.    
1.13.1 Vascular Cell Adhesion Molecule-1(VCAM-1)/ CD106 
This is the main endothelial receptor that plays an important role in mediating 
adhesion of leukocytes to vascular endothelium. In addition to that, it also engages 
in regulation of T-lymphoblast movement through endothelial venular walls. 








1.13.2 Protocadherin 12 (PCDH12)/ VE cadherin 
PCDH12 is a transmembrane protein mainly located at intercellular junctions. 
Intercellular junctions have been shown to control some part of the endothelial 
permeability to plasma proteins and circulating cells. Its expression is 
characteristically noticed in endothelial cells. It is mainly responsible for calcium 
dependent cell to cell adhesion.30,31 
1.13.3 VEGF Receptors 
1.13.3a FLT1/ VEGFR-1 
VEGF regulates endothelial cell cycle through modulating molecular signal 
pathways. The most significant effect of VEGF receptor-1 is controlling the cell 
migration by regulating actin reorganization via the activation of p38 MAK kinase. 
In addition to that, it also triggers activation and movement of monolayer 
phagocytes across an endothelial cell monolayer. This interaction generates 
chemotactic response in polymorphonuclear cells.26,32,33 (Figure 5) 
1.13.3b KDR/ VEGFR-2 
KDR promotes cell migration by controlling cell adhesion and mediates DNA 
synthesis of endothelial cells via the activation of ERK1/2. Furthermore, it also 
enhances vascular permeability during angiogenesis by stimulating the synthesis 






Figure 5:  VEGF Receptors 1 and 2 (Reference: Sharma A, Bandello F, Kuppermann B, 
Makam D, Research Efforts are going beyond targeting VEGF) 
  
1.13.4 Platelet Endothelial Cell Adhesion Molecule-1(PECAM-1)/CD31  
PCAM-1 is a transmembrane glycoprotein located on the blood endothelial cells, 
platelets and on leukocytes. It has been shown to play a major role in 
angiogenesis. It facilitates leukocyte movement through endothelial intercellular 
junction during inflammation. 34-36 
1.14 Innovation   
Angiogenesis play a major role in functional bone regeneration. The current gold 




Due to limitations associated with autografts, and allografts, stem cell-based tissue 
engineering emerged as a viable approach to regenerate biological tissue 
substitute for critical bony defects. 4,7-11 Mesenchymal stem cells (MSCs) from 
different origins (For example; bone marrow, adipose tissue cells, urine) have been 
shown to differentiate to endothelial cells following supplementation of vascular 
endothelial growth factor (VEGF) in media.7-9,11 Limited studies have addressed 
on orofacial tissue derived mesenchymal stem cells. It has been shown that 
deriving stem cells from Orofacial tissues are minimally invasive and easily 
accessible. The origin of GMSCs is from neural crest cells and they differentiate 
into cartilage and bone to form craniofacial skeleton.4 Although, a technological 
development is required to regenerate a highly vascularized and functional bone 
in craniofacial region, to the best of our knowledge, none of the study has ever 
addressed such a technique to differentiate GMSCs to endothelial cells in the 
regenerated bone tissue. In this project, for the first time, we propose to 
differentiate gingival stem cells to endothelial progenitor cells by supplementing 
with VEGF. This project will be innovative in terms of developing a highly 
vascularized and vital bone in the craniofacial region by differentiating GMSCs into 
endothelial cells. It will eliminate drawbacks associated with co-culturing (that is, 
co-culture of endothelial and osteogenic cells) technique. And also, it would be 
possible to use gingival stem cells as the single cell source to enhance 






1.15 Objectives  
The long-term goal of this project is to develop in-vitro pre-vascularized bone tissue 
constructs which will be transplanted to the large defect for regeneration of bone 
with sufficiently functional vascular networks. Thus, the translational significance 
of this project represents the novel tissue engineering approach to regenerate a 
highly vascularized and vital bone during bone regeneration in the craniofacial 
region.   
1.16 Specific Aim 
The aim of this study is to examine the effects of VEGF on induction of in vitro 

















CHAPTER 2 MATERIALS AND METHODS 
2.1 Materials 
Commercially available Recombinant Human VEGF, PECAM antibody were 
purchased from R&D Systems (Minneapolis, MN) was used for the study. Human 
Umbilical Vein Endothelial cells and were obtained from Lonza, (Allendale, NJ). 
Primers used for quantitative PCR were obtained from Life Technologies. All other 
required lab supplies were acquired from Sigma (St. Louis, MO). 
2.2 Overall Study Design  
The methods for isolation of gingival stem cells from human gingiva tissue has 
already been established in our laboratory.  The gingival tissue was obtained from 
the NSU clinics following the guidelines of Institutional Review Board (IRB).  In this 
study, cryopreserved GMSCs were revived and the cells from 5 donors from male 
and female have been used for all experiments. Cells were cultured under 
standard culture conditions. Cells that have reached 70-80 % confluency were 
induced with different concentrations of angiogenic medium (Dulbecco’s modified 
Eagle Medium (DMEM) + 10% fetal bovine serum (FBS) + 1% antibiotics + VEGF 
10, 50, 100 ng/mL) for one week. Human Umbilical Vein Endothelial cells 
(HUVECs) were used as a positive control. The endothelial cell differentiation was 
measured by quantitative PCR, immunofluorescence, tube formation assays. In 
addition to that, scratch assay was performed to determine the migration of 




Figure 6: Overall Methodology Design  
 
2.3 Cell Culture and Characterization of GMSCs 
The GMSCs obtained from human gingival tissues were cultured in 75cm² culture 
flasks in growth medium (DMEM) supplemented with 10% FBS and 1% antibiotic) 
and were incubated at 37°C in 5% CO2 atmosphere. After 72 hours of culture, 
non-adherent cells were removed.37 The growth medium was changed every 2 
days. The cells obtained from passage 2 were subjected to Flow-cytometric 
analysis to confirm positive to mesenchymal markers CD44, CD73, CD90, and 
CD105 and negative to CD34 (hematopoietic stem cells).20 These specific markers 
were measured at the facilities at University of Miami using a fluorescent activated 





2.4 VEGF Treatment to GMSCs   
A recombinant human VEGF protein (Source: Spodoptera frugiperda, Sf 21 
(baculovirus) - derived Ala27-Arg191) obtained from R n D systems, Minneapolis, 
MN (catalogue # 293-VE-050) with a purity of >97%, with endotoxin level <0.01 
EU per 1 μg was used for this study. 
Gingival stem cells at 70- 80% confluency were treated with angiogenic 
differentiation medium (DMEM, 10% fetal bovine serum, 1% antibiotic 
supplemented with different concentrations of VEGF-10, 50, 100 ng/ ml) for 7 days. 
Medium was  changed every 2 days.10 The  cells without VEGF treatment, and 
HUVECs were designated as negative and positive control groups respectively 
(Table 1). Cell morphology was monitored after induction with VEGF. Table 1 
represents control and experimental groups studied for the study. 
 
Control Groups Experimental Group 
Human Umbilical vein endothelial 
cells (HUVECs) - Positive control 
10 ng/ml VEGF treated Gingival Stem 
Cells 
Undifferentiated Gingival stem 
Cells - Negative control 
50 ng/ml VEGF treated Gingival Stem 
Cells  
 100 ng/ml VEGF treated Gingival Stem 
Cells  
 










2.5 Scratch Assay 
This assay typically involves culturing a confluent cell monolayer and then 
displacing a group of cells by creating a scratch through the monolayer. In a 12 
well plate 1x105 per well GMSCs were seeded and these were maintained at 37 °C 
and 5% CO2 for 24 h to permit cell adhesion and the formation of a confluent 
monolayer. These confluent monolayers were then scored with a 1ml sterile pipette 
tip to leave a scratch of approximately 0.4–0.5 mm in width. Culture medium was 
then immediately removed (along with any dislodged cells). The removed medium 
was replaced with a fresh medium which served as control group. 50ng/ml VEGF 
was supplemented to the experimental group. The cell migration was monitored at 
1,4 and 17 hours. The cell migration was then analyzed microscopically by 
capturing images at the beginning and at the regular intervals to see the 











Figure 7: Scratch Assay: The technique involves basic steps 1) cell seeding and 
preparation; 2) making a linear thin scratch “wound” (creating a gap) 3) data acquisition 
through microscopic image capturing and gap measurement at each time point; and 4) data 
analysis. (Reference: Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. 




2.6 Gene Expression by Quantitative PCR  
Cells differentiated for 7 days were harvested and lysed in Trizol. The RNA was 
isolated using Trizol (Invitrogen, Carlsbad, CA) extraction method established in 
our laboratory and quantified. CDNA was prepared using high capacity reverse 
transcription kit (life Science Technologies, Carlsbad, CA) according to 
manufacturer’s recommendations.40 The expression of endothelial marker genes 
VEGF receptors VCAM-1, KDR, PCDH12, FLT-1, and PECAM-1 were measured 






     
           
   
Figure 8: Quantitative PCR Gene Expression Studies  
 
                   
Serial #    Gene   Gene expression  
assay used 
1 PECAM-1 Hs01065279 
2 VCAM-1 Hs01003372 
3 KDR Hs00176676 
4 FLT-1 Hs01052961 
5 PCDH12 Hs01007986 
6 B-Actin Hs00194899 
 
Table 2: Primers used in Quantitative PCR 
 
2.7 Immunofluorescence 
The GMSCs treated with or without 50ng/ml VEGF were cultured for 7 days and 
subsequently fixed with 4% pre-chilled (4°C) paraformaldehyde. The cells were 




5 mins each. The cells were incubated with 2 % BSA, 22.52 mg/ mL glycine in 
PBST (PBS + 0.1 % Tween 20) for 60 mins to block unspecific binding of the 
antibodies. After that, diluted primary antibody (PECAM-1) was added into the cells 
in each well containing 1% BSA in PBST and kept for overnight incubation in 4º C. 
Cells were washed with PBS 3 times for 5 mins each followed by incubating with 
secondary antibody (Goat Anti-mouse IgG Alexa Fluoro-Plus 488). After 
incubation, the cells were washed with PBS. DAPI (life Technologies, Carlsbad, 
CA) was used as counter stain. The cells were then observed under the  
fluorescence microscope.10  
2.8 Tube Formation Assay 
The HGMSCs were treated with 0, 10, 50 and 100 ng/ml VEGF for 7 days. 50 µL 
of Matrigel (mixture of extracellular matrixes; laminin, nidogen, collagen and 
heparan sulfate proteoglycans, Corning) was added to each of the 16 wells in a 
96-well plate and incubated for 1 hour at 37°C to solidify. Cells were then 
trypsinized and suspended. The suspended cells were seeded on top of the 
Matrigel. After incubation for 0,1, 3, 6 and 12 hours,  the capillary like structures 
were examined under the microscope and pictures were captured using Cellsens 







Figure 9: Tube Formation Assay 
 
2.9 Statistical Analysis 
Statistical analysis was performed using the GraphPad Prism 5.0software 
(GraphPad Software, La Jolla, CA, USA). Data presented in this study are means 
± standard deviation of the mean.  For quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR), relative gene expression ratios were 
determined using the 2Δct mathematical model. Samples were analyzed at least 
in five independent experiments (n=5) using triplicates at minimum for quantitative 
PCR. For all other experiments three independent experiments (n=3) were 
conducted. To evaluate differences between or among groups (control group and 
experimental group), analysis of variance (ANOVA) was performed. In order for 










CHAPTER 3 RESULTS 
3.1 Isolation and Culture of Human Gingival Stem Cells 
The isolated cells from the tissue were plated at a density of 2 x 104 cells/cm2 and 
incubated with growth medium (DMEM supplemented with 10% FBS and 1% 
antibiotics).  The cells became 70 to 80% confluent after 3-5 days. The cells 
showed homogenous, tightly adherent, spindle-shaped and fibroblast like 
morphology.  
3.2 Flow Cytometry Analysis 
The cells obtained from passage 2 were subjected to flow cytometry. The flow 
cytometry confirmed expression of surface markers CD105, CD90, CD73 (all 







Figure 10: Flow Cytometry data showing surface markers of Mesenchymal Stem Cells. The 
cells showed over 90% positive to CD73, CD90, CD105 and negative to CD34  
 
3.3 Morphology of Cells after Induction of Angiogenic Medium  
Cell morphology after VEGF treatment was monitored under light microscope.  
Under phase contrast view, plated cells show spindle shaped structures at day 3 
of induction with VEGF (Figure 11B). The cells shape is not exactly like that of 
typical endothelial cells, so called cobble-stone appearance. Majority of cells still 




              
 
Figure 11: Morphology of cells after plating and after VEGF treatment on day 3 and 6 
 
3.4 Scratch Assay 
In- vitro Scratch assay was conducted to track the migration of endothelial cells. 
The images were captured at the beginning, 4 hours and at 17 hours. Results 
showed significant endothelial cell migration towards the scratch as compared to 
control group (Undifferentiated GMSCs with CM only). At 0 hour, cells in 
experimental group just started migrating. We observed more migration of cells in 
experimental groups at 4 hours. At 17 hours, cells migration in VEGF induced cells 






Figure 12: Scratch assay: Control group (CM) showed much slower migration of cells. 50 
ng/ml VEGF induced GMSCs showed more than 90% closure at 17 hours. 
 
3.5 Gene Expression Studies of Various Endothelial Markers of GMSCs  
The expression of endothelial markers genes VEGF receptors (KDR, FLT-1), 
PCDH12 VCAM-1, PECAM-1 were measured at day 7 post VEGF treatment. The 
VEGF enhanced the gene expression of all endothelial markers in a dose 
dependent manner. While VCAM-1 and KDR expression was significantly 
upregulated at all concentrations (P= 0.0041, P= 0.003) respectively, the 
upregulation of PCDH12 (P< 0.0001), FLT1 (P< 0.0001) and PECAM-1 (P< 0.03) 
was maximum at the cells treated with 50ng/ml VEGF.  VCAM-1 expression 
significantly increased 75 % at 10, 50 ng/ml and almost 100% increase at 100 ng/ 
ml (Figure 13). While KDR expression increased by significant 50 % and 75 % at 
50 and 100 ng/ml respectively, there was no significant increase in the cells treated 
with 10ng/ml compared to control (Figure 14).  For PCDH12, the dose dependent 
increase has been observed (Figure 15). As shown in Figure 16, for FLT-1, there 




almost doubled at 50 ng/ml. Furthermore, PECAM-1 showed significant increase 
of 50 % over the control at 50 ng/ml concentration (Figure 17). Overall, the results 
demonstrated a dose dependent increase of endothelial markers. However, there 
was no significant difference between 50ng/ml and 100ng/ml in any of the gene 
expression. The relative gene expression of VCAM-1 has significantly increased 
in GMSCs, however, the expression of all other genes was not comparable to 
HUVEC cells (Data not shown). 
 
Figure 13: GMSCs: Relative Gene Expression of VCAM-1 were analyzed 5 independent 

























Figure 14: GMSCs: Relative Gene Expression of KDR were analyzed 5 independent times 
on 5 different donors, leading to p-value =0.003 
 
 
Figure 15: GMSCs: Relative Gene Expression of PCDH12 were analyzed 5 independent 
















































Figure 16: GMSCs: Relative Gene Expression of FLT-1 were analyzed 5 independent times 
on 5 different donors, leading to p-value <0.0001 
 
 
Figure 17: GMSCs: Relative Gene Expression of PECAM-1 were analyzed 5 independent 



























3.6 Immunofluorescence Assay 
Both HUVECs and GMSCs were treated with 50ng/ml of VEGF for one week. After 
7 days, immunofluorescence assay performed to measure the expression of 
PECAM-1. Immunofluorescence analysis demonstrated the expression of 
PECAM-1 in differentiating GMSCs. Furthermore, results showed expression of 
PECAM-1 in GMSCs is comparable with the expression in HUVECs. (Figure 18)  
              
                          
Figure 18: Immunofluorescence assay: Expression of PECAM-1 was observed in the cell 
membranes of both GMSCs with 50 ng/ ml VEGF treatment and HUVECs. (Figures B, D). 
Figure C and E showed magnified picture of cell for both VEGF induced gingival stem cells 









3.7 Tube Formation Assay 
The functionality of the differentiating GMSCs angiogenic potential was assessed 
in tube-forming assays, demonstrating that seeding of 3x103 cells on Matrigel 
started forming tubes from 1 hour and it continued until 6 hours.  
While the experimental group was the GMSCs induced with 10, 50 and 100 ng/ml 
of VEGF for 7 days, the undifferentiated GMSCS (Cells treated with complete 
medium at 0 ng/ml VEGF) served as control group. The functional behavior of the 
differentiated cells showed more capillary like structures. Tube formation was 
compared at 0, 1, 3 and 6 hours. At 0 hour, cells were just plated and all 
concentrations look similar (Figure 19). At 1 hour, cells started organizing slightly 
for tube formation in both control and experimental group. However, that was 
prominent in the cells treated with 10 ng/ml and 50ng/ml (Figure 20).  After 3 hours, 
in 10 and 50 ng/ml, the cell clusters showed branching and tight interconnections, 
while few capillaries were detected at 100 ng/ml concentration and no capillaries 
formation was seen in control group (Figure 21). 6 hours afterwards, tube formation 
was greatly enhanced at all concentrations. We observed increased density of cell 
clusters at 10, 50 ng/ ml concentration. Tube formation interconnection was also 
noticed in undifferentiated cells with CM only. At 100 ng/ ml, short tube formation 
was observed and we noticed initiation of disintegration of capillaries (Figure 22). 
After 12 hours, capillaries fully disintegrated and no more tube formation was 
visible. (Figure 23) 





             
         
 
   Figure 20: Tube formation assay at 1 hour: Cells started organizing for  
   tube formation, however this was more prominent in cells at 10 and 50 ng/ml      
 






    Figure 21: Tube formation assay at 3 hours: Cells started showing branching  
    and interconnections at 10 and 50 ng/ml, while few capillaries were detected at  
    100 ng/ml concentration.  No capillaries formation was seen in undifferentiated  




    Figure 22: Tube formation assay at 6 hours: Tube formation was greatly  





    Figure 23: Tube formation assay at 12 hours: Capillaries disintegrated and no  




















CHAPTER 4 DISCUSSION AND CONCLUSIONS 
4.1 Discussion  
Mesenchymal stem cells (MSCs) are of great interest in regenerative medicine as 
they have promising potential for clinical use. MSCs are pluripotent progenitors 
that can differentiate into a variety of cell types while maintaining the self-renewal 
property. Their applications have been extensively studied in bone tissue 
engineering. 4,7-11 However, vascularization remains a challenge in bone tissue 
engineering. Vasculature is essential for bone formation and bone remodeling 
during fracture healing. Studies have shown that endothelial cells can enhance 
bone regeneration ability.7 Mature endothelial cells have been used for 
vascularization in bone tissue engineering, but these have limited proliferative 
capacity and cells are not sufficient for repair and reconstruction of blood vessels 
during bone regeneration.12 Sufficient evidences in the past indicate that 
mesenchymal stem cells in- vitro have the potential to differentiate into endothelial 
progenitor cells.9,10,41 Transdifferentiation of MSCs to endothelial cells have many 
advantages as serve as autologous stem cell source with highly proliferative with 
self-renewing capability. Differentiating MSCs to endothelial cells have added 
advantage, as the endothelial progenitor cells are more proliferative than 
differentiated endothelial cells.12 MSCs differentiating into endothelial cells have 
been reported in bone marrow derived stem cells, adipose derived stem cells and 
stem cells derived from Wharton’s jelly.7,10,12,41,42  The angiogenic differentiation of 
dental pulp derived stem cells have been reported recently.43 Indeed, the stem 




networks.43,44  VEGF has pivotal role on endothelial cell proliferation, migration and 
initiating and regulating angiogenesis.6,13 Neovascularization induced by VEGF 
represents an appealing approach for bone tissue engineering. Many scientists 
explored the differentiation of MSCs utilizing VEGF.  For example, Oswald et al. 
reported the differentiation of human bone marrow -derived mesenchymal stem 
cells to endothelial progenitor cells with VEGF activation.10 Similarly, Cao et al. 
have demonstrated that the human adipose tissue-derived stem cells differentiated 
into endothelial progenitor cells in-vitro with VEGF and b-FGF activation.9 These 
evidences indicated that VEGF can support the differentiate mesenchymal stem 
cells into endothelial progenitor cells (EPC). EPC have a higher survival rate and 
10 times more proliferative as compared to mature endothelial cells.7,12   In this 
study, we have investigated the effect of vascular endothelial growth factor (VEGF) 
to induce the differentiation of GMSCs into endothelial lineage.  
Our approach is to utilize the minimal dose of VEGF to induce the angiogenic 
differentiation in GMSCs.  In this study, we used different concentrations of VEGF 
(10, 50, 100 ng/ ml) were tested for its ability to induce endothelial differentiation 
from GMSCs in vitro. After 7 days of VEGF treatment with different concentrations, 
gene expression of angiogenic marker genes was measured using quantitative 
PCR. To confirm the results immunofluorescence and tube formation assay was 
conducted. The overall results indicated that VEGF induced stem cell 




we have used consists of DMEM with 10% Fetal Bovine Serum (FBS) and 1% 
antibiotics supplemented with VEGF. Table 3 gives the details of culture conditions 
of various researchers used.  
 
Table 3: Culture Medium used in various studies  
For example, Oswald et al used 2% FBS in the culture medium supplemented with 
VEGF,10 however, in our study the cells we used 10% FBS in culture medium, as 
our pilot study conducted with 2% and 5% FBS in culture media demonstrated that 
the cells could not survive in low concentrations of FBS (either 2% or 5%).  In our 
study, we have initially used various concentrations of VEGF for gene expression 
studies and tube formation assay. Our data revealed that 50ng/ml was the optimal 
concentration at which the maximal upregulation of marker genes and vessel 




Cell migration is the coordinated movement of a group of cells that maintain the 
inter cellular connections and collective polarity. Cell migration studies are 
hallmark in angiogenesis, would healing and cancer invasion.  It can be studied by 
a variety of methods; one of the popular methods, which is very often used, is the 
scratch assay or wound healing assay.38 Our studies indicated that VEGF 
enhanced the cell migration compared to untreated cells. Our data is in agreement 
with the studies of Fiedler et al.45 They demonstrated that VEGF participates 
induce the migration of bone marrow derived progenitor cells. Cell migration is a 
key understanding process in wound healing.46 Thus our studies indicated that 
VEGF has a potential role inducing cell migration and wound healing process.45,46 
VEGF is a key regulator of angiogenesis through cell migration and proliferation of 
vascular endothelial cells.47 Many other researchers also demonstrated that VEGF 
has a significant role in the cell migration.45,46 Our data showed that the cells 
started migrating in VEGF treated cells and the migration rate increased over time 
compared to control (cells treated with CM).  The VEGF treated cells migrated and 
almost 90 % closed the scratch 17 hours. A similar pattern was observed in several 
earlier studies.38,39,45,46  
The results of quantitative PCR demonstrated that the endothelial markers VCAM-
1, PECAM-1, KDR, FLT-1, PCDH12 in GMSCs induced with VEGF for 7 days 
significantly upregulated compared to undifferentiated cells.  When compared with 
HUVEC cells, the VCAM-1 expression is strikingly significantly upregulated than 
the expression in HUVEC cells. However, the expression of other genes was 




pattern of down regulation was reported earlier, suggesting that a tissue specific 
hierarchical pattern of gene expression.41 Duration of differentiation and the culture 
medium used for angiogenic medium might be contributing factors. While 
differentiation of Wharton’s Jelly derived stem cells cultured in M199 medium 
occurred in 4 days, in SHED cultured in VEGF induced differentiation medium have 
not expressed endothelial markers until 28 days.41,48 In dental pulp derived stem 
cells (DPSC) cultured in EGM medium, and bone marrow stem cells cultured in  
VEGF, basic fibroblast growth factor (bFGF), insulin like growth factor (IGF), and 
epidermal growth factor (EGF) expressed angiogenic markers in 7 days and 14 
days respectively.43,49 From these studies it is evident that culture medium and 
duration of differentiation contribute important factors. 
Angiogenesis is a tightly organized sequence of cellular events characterized 
including endothelial cell migration, invasion and differentiation into capillaries.42 
In vitro endothelial tube formation assays are used as a model for studying 
endothelial differentiation. This assay is employed to determine the ability of 
various compounds such as growth factors or drugs to promote or inhibit the tube 
formation. Essentially, this assay measures the ability of cells plated at sub 
confluent densities with appropriate extracellular matrix support to form capillary 
like structures.42,49  Our data on tube formation assay revealed that VEGF induced 
vascular like network in classical tube formation assay.  GMSCs induced with 
VEGF at 10 and 50 ng/ml formed the tubes with maximum at 6 hours.  After 8 
hours, the cells started clumping, and we could observe large clumps at 12-hour 




center and start organizing tubule. A dose dependent trend has been seen in our 
study.  The tubes formed with dense branching at 10ng and 50 ng/ml.  In 50 ng/ml 
the tube density was maximum. 
4.2 Conclusions 
The regeneration of defect and lost tissue in oral region is the goal of our stem cell 
research. For the first time, our study demonstrated that GMSCS were able to 
differentiate into endothelial like cells. The advantage of utilizing the GMSCs 
isolated from gingiva tissue is that, they are obtained as a discarded tissue in the 
clinics during flap surgery procedures or third molar extractions. Furthermore, they 
can serve as autologous stem cell source with robust proliferation rate and minimal 
risk of immune-rejection. In addition to their neural crest origin, the high self-
renewal capacity, wound healing ability and their plasticity makes GMSCs suitable 
for bone tissue engineering applications. On the contrary, the stem cells developed 
from bone marrow cells require the invasive surgery. Additionally, the endothelial 
differentiation ability of GMSCs, will expand their scope for many other tissue 
engineering applications including bone and cardiac tissue engineering 
applications. Thus, our study addressed, in part, the existing challenges to develop 
a vascularized tissue engineered bone. Further, in vitro and in vivo studies are 
warranted to gain more insights on the effects of VEGF as enhancer of 
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